Bausch + Lomb (BLCO) Q2 2026: Premium IOLs Surge 175% Bolsters Surgical Segment Transformation
Bausch + Lomb’s second quarter accelerated broad-based growth, led by a dramatic premium intraocular lens (IOL) expansion that is reshaping its surgical business. Margin expansion and strong cash flow conversion reinforce confidence in hitting ambitious multi-year targets amid sustained pipeline investments.
Summary
- Strategic Growth Momentum: Broad-based revenue and margin gains reflect durable execution across pharmaceuticals, surgical, and vision care segments.
- Operational Leverage: Structural cost improvements and premium mix shifts drive profitability and cash flow, enabling deleveraging.
- Innovation Pipeline Depth: Multiple near- and long-term product milestones support sustained competitive positioning.
Business Overview
Bausch + Lomb is a global eye health company generating revenue primarily through three segments: Vision Care (contact lenses and consumer eye health products), Surgical (implantables such as intraocular lenses, surgical equipment, and consumables), and Pharmaceuticals (branded prescription drugs for eye diseases). The company’s business model combines product innovation, commercial execution, and operational efficiency to drive growth and margin expansion.
Performance Analysis
Bausch + Lomb reported second quarter 2026 revenue of $1.394 billion, an 8% increase on a constant currency basis compared to the prior year. Growth was broad-based across all segments, with the Surgical segment leading with a 16% constant currency increase, fueled by a 175% surge in premium IOL sales. Pharmaceuticals and Vision Care also posted solid gains of 14% and 4%, respectively, demonstrating balanced portfolio strength.
Adjusted EBITDA rose 28% year-over-year to $246 million, with margins expanding 260 basis points to 17.6%. This margin improvement was driven by favorable product mix shifts toward higher-margin premium categories, productivity gains, and disciplined selling, general and administrative (SG&A) expense management. Cash flow from operations more than tripled to $161 million, reflecting strong conversion of earnings into liquidity and enabling a full turn reduction in net leverage to 4.7 times.
- Segment Growth Drivers: Premium IOL portfolio expansion underpinned surgical growth, while pharmaceuticals benefited from strong Mibo and Zydra performance in dry eye treatment.
- Margin Expansion Levers: Mix shifts toward premium products, manufacturing efficiencies, and SG&A leverage contributed to sustained profitability gains.
- Cash Flow and Capital Efficiency: Working capital improvements and operational discipline accelerated cash conversion, supporting deleveraging priorities.
Overall, the financial results validate the company’s strategic framework of driving sustainable top-line growth while expanding margins and investing in innovation.
Executive Commentary
"Broad-based revenue growth, leverage in the P&L, margin expansion and conversion to cash flow. These have been themes since we unveiled our three-year plan for growth at Investor Day last November, and in the second quarter progress continued at an accelerated pace."
Brent Saunders, Chairman and Chief Executive Officer
"Revenue growth and margin expansion are now also translating into stronger cash generation and deleveraging to strengthen the balance sheet. This is the progression we outlined. Rejuvenating Revenue Growth, Expanding Margins, and now converting the stronger earnings into cash and improving our leverage."
Sam Eldessouky, Chief Financial Officer
Strategic Positioning
1. Premium IOL Portfolio Driving Surgical Transformation
The surgical segment’s 175% reported growth in premium intraocular lenses (IOLs) is a clear signal of successful execution of a premium-led strategy. Premium IOLs now represent 13% of surgical revenue, up from 6% in 2025, compounding the portfolio shift. This mix shift not only boosts revenue but also expands margins due to higher profitability of premium products. The company’s deliberate focus on innovation with products like Envista, Aspire, Envy, and upcoming LUX family offerings is designed to sustain this trajectory well into the latter half of the decade.
2. Operational Excellence and Manufacturing Optimization
Bausch + Lomb is enhancing operating leverage through supply chain streamlining and internalizing more premium product manufacturing. These efforts reduce costs, improve customer loyalty through reliability, and create a scalable platform for consumables and implantables growth. The operational discipline is evident in SG&A reductions as a percentage of revenue and productivity gains translating into margin expansion.
3. Robust Pharmaceuticals Growth Anchored by Dry Eye Franchise
The Pharmaceuticals segment continues to be a growth engine, led by Mibo and Zydra, which together delivered 27% combined revenue growth year-to-date. Mibo’s rapid onset of efficacy and expanding Medicare coverage underpin its strong momentum. This diversified pharmaceutical portfolio addresses a large unmet medical need in dry eye disease, positioning Bausch + Lomb as a market leader in this category.
4. Vision Care Stability and Innovation Pipeline
Vision Care revenue grew 4% on a constant currency basis, driven by balanced global growth across daily SiHy, Biotrue ONEday, and ULTRA monthly contact lenses. The company’s ongoing product innovation and disciplined global rollout schedule aim to maintain this steady growth trajectory. The contact lens business benefits from structural tailwinds including aging populations and increasing screen time.
5. Pipeline Depth Balancing Near-Term Milestones and Long-Term Innovation
Bausch + Lomb’s pipeline encompasses a diverse set of assets across dry eye disease, surgical devices, retinal diseases, and emerging AI and computational biology applications. Near-term catalysts include FDA submission for the Elios implant-free MIGS glaucoma laser and data readouts for dual action dry eye and ocular surface pain candidates. Longer-term programs, including the enVista Beyond investigational IOL, support sustained innovation-driven growth.
Key Considerations
Bausch + Lomb’s Q2 results underscore the effectiveness of its multi-pronged strategy emphasizing portfolio premiumization, operational discipline, and innovation investment. Key considerations for investors include:
- Market Recovery and Confidence: Surgical segment growth surpasses pre-recall baselines, signaling restored customer trust and expanding market share.
- Margin Expansion Sustainability: Mix shifts and cost efficiencies appear structural, but ongoing investment in R&D tempers margin upside.
- Cash Flow Conversion: Working capital improvements and operational leverage support accelerating cash flow, critical for deleveraging and reinvestment.
- Competitive Positioning: The company remains well-positioned against new market entrants in premium IOLs and dry eye therapeutics.
- Innovation Pipeline Execution: Upcoming product launches and clinical milestones will be key to sustaining growth momentum beyond 2026.
Risks
Risks include potential regulatory delays, competitive pressures from new entrants in premium IOL and dry eye markets, macroeconomic factors impacting consumer spending, and execution risks associated with pipeline development. Additionally, geopolitical and tariff uncertainties could affect supply chains and cost structures. Management’s guidance assumes stable currency and tariff environments, which remain potential headwinds.
Forward Outlook
For the third quarter of 2026, Bausch + Lomb expects to sustain growth momentum with normalized seasonality. Full-year 2026 guidance was raised to $5.44 billion to $5.54 billion in revenue, reflecting 5.8% to 7.7% constant currency growth, and adjusted EBITDA guidance increased to $1.025 billion to $1.075 billion. Management anticipates continued margin expansion with adjusted EBITDA growing nearly three times faster than revenue and plans to maintain R&D investment at approximately 7.5% to 8% of revenue.
Takeaways
Bausch + Lomb’s Q2 performance confirms the company’s strategic transformation into a premium-focused, innovation-driven eye health leader with strong operational discipline.
- Growth Quality and Sustainability: Broad-based segment growth with premium IOLs as a transformative driver signals durable competitive advantage and margin expansion potential.
- Execution Discipline: Improved SG&A efficiency and manufacturing optimization are delivering structural margin gains and cash flow, enhancing financial flexibility.
- Pipeline as Growth Engine: Robust near- and long-term product development milestones underpin confidence in sustained innovation-led growth beyond 2026.
Conclusion
Bausch + Lomb’s second quarter results demonstrate accelerating momentum across all segments, driven by a premium portfolio shift and operational excellence. The company’s disciplined execution and innovation pipeline position it well to meet or exceed its three-year growth and margin targets while strengthening its balance sheet.
Industry Read-Through
Bausch + Lomb’s success in premium IOL adoption and dry eye pharmaceuticals highlights broader industry trends favoring product premiumization and specialized therapeutics in eye care. The company’s ability to convert margin expansion into cash flow while investing in innovation offers a model for peers navigating competitive pressures and evolving patient needs. Additionally, the growing integration of AI and digital health technologies in eye care, as exemplified by Bausch + Lomb’s Orphea platform, signals a sector-wide shift toward technology-enabled patient management and procedural efficiency.